A new plain language summary (PLS) is now available, developed to make key research findings more accessible to healthcare professionals and patients alike.

The PLS accompanies the manuscript “Management of adverse events occurring with MAPK-directed therapies in patients with pediatric low-grade glioma: An expert Delphi consensus initiative,” which presents the results of an expert Delphi consensus initiative on managing side effects associated with MAPK-directed therapies in children with low-grade glioma.

Developed on behalf of the author group by Bioscript, the PLS translates the study’s clinical findings into clear, patient-friendly language, supporting better understanding among both HCPs and the patients and families affected by these treatments.

Read the full manuscript here.